{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:02:11Z","timestamp":1791140531381,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.jaad.2008.12.001","type":"journal-article","created":{"date-parts":[[2009,2,14]],"date-time":"2009-02-14T10:23:56Z","timestamp":1234607036000},"page":"781-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Thrombocytopenia associated with the use of anti\u2013tumor necrosis factor\u2013\u03b1 agents for psoriasis"],"prefix":"10.1016","volume":"60","author":[{"given":"Alexandra Maria Giovanna","family":"Brunasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Massone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2008.12.001_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1365-2133.1996.d01-1035.x","article-title":"Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease","volume":"135","author":"Nevitt","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.001_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.120568","article-title":"The immunologic basis for the treatment of psoriasis with new biologic agents","volume":"46","author":"Krueger","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.12.001_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(02)07718-8","article-title":"Adverse reactions to TNF-alpha blockers in rheumatoid arthritis","volume":"359","author":"Day","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.12.001_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-143-10-200511150-00028","article-title":"Immune thrombocytopenia associated with efalizumab therapy for psoriasis","volume":"143","author":"Warkentin","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.12.001_bib5","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/kel204","article-title":"TNF alpha blocker-induced thrombocytopenia","volume":"45","author":"Pathare","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.12.001_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/gut.2007.123547","article-title":"Infliximab and adalimumab-induced thrombocytopenia in a woman with colonic Crohn's disease","volume":"56","author":"Salar","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jaad.2008.12.001_bib7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.001_bib8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/ard.2003.006775","article-title":"Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients","volume":"63","author":"Feletar","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.12.001_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2340\/00015555-0400","article-title":"Transient and slight thrombocytopaenia induced by etanercept during treatment of psoriatic arthritis","volume":"88","author":"Stinco","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2008.12.001_bib10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10067-006-0229-y","article-title":"A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap\/rheumatoid arthritis","volume":"26","author":"Hamaguchi","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2008.12.001_bib11","doi-asserted-by":"crossref","first-page":"W62","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4","article-title":"Severe neutropenia and thrombocytopenia associated with infliximab","volume":"139","author":"Vidal","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.12.001_bib12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2133.2008.08514.x","article-title":"Psoriasis treatment with etanercept and efalizumab: clinical strategies influencing treatment outcome","volume":"158","author":"Driessen","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.001_bib13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/rheumatology\/keg341","article-title":"Pancytopenia in a patient with scleroderma treated with infliximab","volume":"42","author":"Menon","year":"2003","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2008.12.001_bib14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#","article-title":"Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines","volume":"42","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.12.001_bib15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.7326\/0003-4819-129-11_Part_1-199812010-00009","article-title":"Drug-induced thrombocytopenia: a systematic review of published case reports","volume":"129","author":"George","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2008.12.001_bib16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1365-2141.2003.04547.x","article-title":"Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients","volume":"122","author":"Neylon","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2008.12.001_bib17","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.12.001_bib18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.12.001_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.hoc.2007.06.005","article-title":"Drug-induced thrombocytopenia","volume":"21","author":"Visentin","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2008.12.001_bib20","doi-asserted-by":"crossref","first-page":"R545","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2008.12.001_bib21","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","article-title":"In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL","volume":"167","author":"Via","year":"2001","journal-title":"J Immunol"},{"issue":"Suppl 3","key":"10.1016\/j.jaad.2008.12.001_bib22","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1186\/ar570","article-title":"Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha\/beta in immunity and autoimmunity","volume":"4","author":"McDevitt","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.jaad.2008.12.001_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajh.21135","article-title":"Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept","volume":"83","author":"Litton","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2008.12.001_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ajh.10331","article-title":"Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept","volume":"73","author":"McMinn","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2008.12.001_bib25","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ibd.20209","article-title":"Infliximab: an alternative treatment for refractory immune thrombocytopenic purpura related to Crohn's disease?","volume":"13","author":"Lazaraki","year":"2007","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208024729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208024729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:14:01Z","timestamp":1759270441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962208024729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0190962208024729"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2008.12.001","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombocytopenia associated with the use of anti\u2013tumor necrosis factor\u2013\u03b1 agents for psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2008.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}